Glenmark Pharmaceuticals receives ANDA approval for Sevelamer HydrochlorideTablets, 400 mg and 800 mg
Deepthi | Myequity news | Date : 11-02-2019 9:40:00 IST
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg, a generic version of Renagel®1 Tablets, 400 mg and 800 mg, of Genzyme Corporation.
According to IQVIATM sales data for the 12 month period ending December 2018, the Renagel® Tablets, 400 mg and 800 mg market2 achieved annual sales of approximately $102.1 million.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2018). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.